METHODS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
First Claim
Patent Images
1. A method, comprising contacting a cell with a C9ORF72 antisense transcript specific inhibitor.
0 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are methods for reducing expression of C90RF72 antisense transcript in an animal with C90RF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 antisense transcript specific inhibitors include antisense compounds.
10 Citations
51 Claims
- 1. A method, comprising contacting a cell with a C9ORF72 antisense transcript specific inhibitor.
-
2. A method, comprising contacting a cell with a C9ORF72 antisense transcript specific inhibitor and a C9ORF72 sense transcript specific inhibitor.
-
3. A method, comprising contacting a cell with a C9ORF72 antisense transcript specific inhibitor;
- and thereby reducing the level or expression of C9ORF72 antisense transcript in the cell.
-
4. A method, comprising contacting a cell with a C9ORF72 antisense transcript specific inhibitor and a C9ORF72 sense transcript specific inhibitor;
- and thereby reducing the level or expression of both C9ORF72 antisense transcript and C9ORF72 sense transcript in the cell.
- View Dependent Claims (6)
- 9. A method, comprising administering to an animal in need thereof a therapeutically effective amount of a C9ORF72 antisense transcript specific inhibitor.
- 11. A method, comprising coadministering to an animal in need thereof a therapeutically effective amount of a C9ORF72 antisense transcript inhibitor and a therapeutically effective amount of a C9ORF72 sense transcript inhibitor.
-
15. A method, comprising:
-
identifying an animal having a C9ORF72 associated disease; and administering to the animal a therapeutically effective amount of a C9ORF72 antisense transcript specific inhibitor. - View Dependent Claims (16, 19, 25, 26, 27, 34, 36, 37, 38)
-
-
17. A method, comprising:
-
identifying an animal having a C9ORF72 associated disease; and coadministering to the animal a therapeutically effective amount of a C9ORF72 antisense transcript specific inhibitor and a therapeutically effective amount of a C9ORF72 sense transcript inhibitor. - View Dependent Claims (18, 20)
-
-
33. The method of claim 33, wherein the C9ORF72 antisense transcript associated RAN translation products are any of poly-(proline-alanine), poly-(proline-arginine), and poly-(proline-glycine).
-
35. The method of claim 35, wherein the parental administration is any of injection or infusion.
Specification